Decoding the DNA of drug launches.
Every launch carries a genetic code: its treatment design, regulatory posture, disease profile, market context, and the experience of the team behind it. That code is set long before approval, and it is far more predictive than most people realize.
The Launch Success Code™ is not a report to read once. It is a diagnostic that turns a generic success benchmark into an asset-specific launch agenda.
Research across 198 FDA novel approvals (2016 to 2024), tested across 40 situational variables. To our knowledge, the broadest factor analysis of launch performance published to date.
| Gene | This launch | Signal strength |
|---|---|---|
| TREATMENT DESIGN | mAb, monthly regimen, ... | |
| REGULATORY POSTURE | PRV redeemed, no REMS, ... | |
| DISEASE PROFILE | Severe chronic, mid-size population, ... | |
| MARKET CONTEXT | Two approved competitors, ... | |
| COMMERCIAL POSTURE | Specialty pricing tier, ... | |
| ORGANIZATIONAL EXPERIENCE | Experienced team, first company launch, ... |
Excerpt only: the full Code analyzes 40 variables across these six families. Signal strength is illustrative; detailed research findings are available in the white paper.
More than half of new therapy launches miss their pre-launch forecast.
Independent studies converge on this finding.The Launch Success Code™ goes further: it quantifies how badly launches miss, how far the outliers overdeliver, and which factors decode the difference.
Plenty of launch research exists. Most of it examines a handful of variables, and almost none of it, to our knowledge, tests them for statistical significance. We built the Launch Success Code™ to answer a different question: which specific factors, formally tested, actually shift the odds for a specific launch.
40 launch variables coded per launch, spanning treatment design, regulatory context, disease profile, market context, commercial posture, and organizational experience. Prior public studies typically examine a handful.
Every variable was formally tested against outcomes. Of 40 variables, only 10 showed statistically meaningful associations with beating or missing forecasts. The non-findings matter as much as the findings.
Most studies stop at "missed forecast." The Code separates extremely severe misses (under 40% of forecast) from moderate-to-severe ones, and studies the significant outperformers (over 120%) just as closely as the failures.
Performance is measured against pre-launch consensus forecasts, not absolute dollars. Part of what the data shows is a forecast-quality effect layered on adoption dynamics. We keep that caveat front and center.
Of 198 launches with clean pre-launch forecasts and reported sales: just over one-third significantly exceeded expectations, 58% missed, and roughly 35% were extremely severe underperformers, delivering less than 40% of forecasted year-one sales. At that level, a miss can blow a hole in a big-pharma P&L; for a single-asset company, it can be fatal.
Oncology launches outperform. A favored heuristic in portfolio reviews. In our data, oncology vs non-oncology showed no independent predictive power.
Specialty beats primary care. Often assumed, rarely tested. The specialty vs primary-care split did not survive testing.
Orphan designation lifts the odds by itself. On its own, the designation carried no independent signal.
A Fast Track or Breakthrough badge predicts success. Regulatory badges alone told us nothing about outcomes.
Big company, better launch. Simple company-size proxies showed no independent effect.
The stories told in launch planning rooms and investment committees are, statistically, weak genes.
Read any launch, at any stage, against the Code: its treatment design, regulatory posture, disease and market context, commercial posture, and organizational experience. Every launch has a DNA profile. Most teams have never seen theirs written down.
Place that profile on the generic launch success track: how launches with this DNA have historically performed against expectations, including the odds of significantly exceeding, meeting, or severely missing forecasts.
Identify the specific drivers and barriers for this launch: which genes are working for it, which against it, and, most importantly, the implications for where launch strategy design and resources should concentrate.
The DNA of a launch shows how launches with this profile have typically played out, benchmarked against the past. It is not a prediction: a launch team can significantly shape performance. The Code charts the course toward beating the odds.
The Phase I findings of the THRIVE Launch Success Code™ in a concise, board-ready document.
Get notified →The Diagnose step, applied to your launch. A short set of non-identifying questions, 3 to 5 minutes: therapeutic area, modality, treatment design, competitive context, organizational experience. No confidential information requested. You receive a report by email with your launch DNA profile, how launches like yours have performed, the key drivers and barriers specific to your situation, and where THRIVE suggests the launch team should focus.
Get notified →Methodology and caveats. From ~460 FDA CDER/CBER novel approvals (2016 to 2024), we retained 198 launches with matchable pre-launch consensus forecasts and reported sales. Each was classified by actual vs forecast year-one sales into four bands: over 120%, 80 to 120%, 40 to 80%, and under 40%. 40 variables were tested univariately for association with outcomes. Throughout, success and failure mean performance relative to pre-launch expectations, not absolute revenue: well-understood markets tend to carry better-calibrated forecasts, while novel and rare settings are structurally more exposed to over-optimistic expectations.
If your organization is launching a new therapy where failure is not an option, let’s talk.
Start a conversation